BioSpace News Archive

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a business update and announced financial results for the fourth quarter ended December 31, 2019.

Innovative collaboration will improve kidney disease care and lower costs for Cigna customers

Met primary endpoint in Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia and demonstrated favorable safety profile with no significant weight gain, somnolence or extrapyramidal side effects relative to placebo

New platform drives industry forward and opens up a new era for NGS technology

QIAGEN announced that it has begun shipments to the United States of its new QIAstat-Dx Respiratory SARS-CoV-2 Panel test to aid in diagnosing patients infected with the novel COVID-19 coronavirus under a new Policy of the U.S. Food and Drug Administration announced on March 16. QIAGEN will submit this week the related Emergency Use Authorization to the FDA.

Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced the appointment of David Happel as Chief Executive Officer.

Novavax, Inc. announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M™ adjuvant, in adults aged 65 and older.